Publications in collaboration with researchers from Yale University (1)

2020

  1. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    The Lancet Oncology, Vol. 21, Núm. 12, pp. 1574-1588